Safety and benefit considerations for menopausal hormone therapy

  title={Safety and benefit considerations for menopausal hormone therapy},
  author={James H. Pickar and David F Archer and Risa Kagan and JoAnn V. Pinkerton and Hugh S. Taylor},
  journal={Expert Opinion on Drug Safety},
  pages={941 - 954}
ABSTRACT Introduction: While benefits and risks of hormone therapy (HT) have been shown in rigorous randomized, controlled trials, clinical use and further study have discovered effects of age, time of HT initiation, and differential effects of various regimens and administration routes on its safety profile. Areas covered: The safety of HT with regard to cardiovascular disease, thrombosis, the endometrium, the breast, and cognition was reviewed. Differential safety effects of estradiol versus… Expand
Hormone Therapy and Effects on Sporadic Alzheimer's Disease in Postmenopausal Women: Importance of Nomenclature.
To progress forward and allow unbiased interpretation, it is no longer acceptable to group HT formulations together as a homogenous group, and differentiation between compounds that exhibit beneficial actions and those that do not and whether these effects are specific or generalized. Expand
Choice of progestogen for endometrial protection in combination with transdermal estradiol in menopausal women
  • A. Mueck, T. Römer
  • Medicine, Biology
  • Hormone molecular biology and clinical investigation
  • 2018
The aim of this review was to summarize data on the endometrial effects of the different progestogens and to provide practical recommendations for the choice of progestogen (type and dosing), with a focus onendometrial protection when using TE, especially when using the novel estradiol (E2) spray. Expand
Thromboembolic safety profile of low-dose estradiol (valerate) in combined hormonal preparations: Implications for the development of new hormonal endometriosis and uterine fibroid therapies
It is concluded that the risk of E2/E2Val-norethindrone acetate in pre-menopausal users is unlikely to be higher than the known risk of COCs containing EE ⩽ 30 µg-progestin. Expand
Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR)∗
All doses of TX-001HR provided endometrial protection and were associated with an improved bleeding profile over time; older age, further last menstrual period, or lower baseline E2 may predict amenorrhea with TX-002HR. Expand
Complementary and alternative medicine for natural and treatment-induced vasomotor symptoms: An overview of systematic reviews and meta-analyses.
Evidence has shown that acupuncture, hypnosis, paced respiration, cognitive behavioural therapy, genistein, soy isoflavones, S-equol, combined preparations of black cohosh, and omega-3 supplements could significantly reduce VMS. Expand
Climacteric symptoms and quality of life in yoga practitioners.
Yoga practice may represent an efficient non-pharmacological approach to manage and prevent climacteric symptoms and quality of life in regular yoga practitioners between 40 and 65 years old. Expand
Prevalence and practice of oestrogen use among the male gym participants
The results indicate that 6.1 per cent of the surveyed male participants abused a combination of oestrogen and progesterone for breast enlargement, which was significantly more likely among males who had longer durations of gym participation. Expand
Genistein and Selected Phytoestrogen-Containing Extracts Differently Modulate Antioxidant Properties and Cell Differentiation: an in Vitro Study in NIH-3T3, HaCaT and MCF-7 Cells.
This study demonstrates that various phytoestrogen- containing plant extracts and genistein are able to specifically modulate antioxidant properties and differentiation of studied cells. Expand
1,3-Dicaffeoylquinic Acid as an Active Compound of Arctium lappa Root Extract Ameliorates Depressive-Like Behavior by Regulating Hippocampal Nitric Oxide Synthesis in Ovariectomized Mice
It is suggested that 1,3-diCQA regulates nNOS in an estrogen recepters-independent manner to increase NO production in OVX mice and mitigated depression-like behaviors in mice treated with AE. Expand
Thrombosis and Gestagens
Карева Елена Николаевна — д. м. н., профессор кафедры молекулярной фармакологии и радиобиологии ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» Минздрава России. 117997, г. Москва, ул. Островитянова, д. 1.Expand


Current recommendations: what is the clinician to do?
Assessment of whether the patient has moderate to severe menopausal symptoms is the primary indication for initiating systemic HT, and the use of risk stratification and personalized risk assessment offers promise for improved benefit-risk profile and safety of HT. Expand
Progestogen safety and tolerance in hormonal replacement therapy
Short-term clinical studies, observational, and in animal and in vitro studies indicate that both micronized progesterone and dydrogesterone are the safer progestogens with an acceptable metabolic profile. Expand
Effects of combination estrogen plus progestin hormone treatment on cognition and affect.
The effect of CEE + MPA on cognitive function varies across cognitive domains in older women, reflecting both possible beneficial and detrimental actions of ovarian steroids on the aging brain. Expand
Menopausal Symptoms and Treatment-Related Effects of Estrogen and Progestin in the Women's Health Initiative
Estrogen plus progestin relieved some menopausal symptoms, such as vasomotor symptoms and vaginal or genital dryness, but contributed to treatment-related effects,such as bleeding, breast tenderness, and an increased likelihood of gynecologic surgery. Expand
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD. Expand
Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol.
Oral estradiol therapy was associated with less progression of subclinical atherosclerosis (measured as CIMT) than was placebo when therapy was initiated within 6 years after menopause but not when it was initiated 10 or more years afterMenopause. Expand
Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials.
The longer-term influence of menopausal HT on breast cancer incidence in the 2 Women's Health Initiative randomized clinical trials was reported to report, with findings that the higher breast cancer risk seen during intervention was followed by a substantial drop in risk in the early postintervention phase, but a higher cancer risk remained during the late postinterventions follow-up. Expand
Breast cancer after use of estrogen plus progestin in postmenopausal women.
The increased risk of breast cancer associated with the use of estrogen plus progestin declined markedly soon after discontinuation of combined hormone therapy and was unrelated to changes in frequency of mammography. Expand
Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.
In postmenopausal women, continuous combined estrogen plus progestin decreases endometrial cancer incidence and deaths after extended follow-up of the Women's Health Initiative randomized clinical trial. Expand
Hormone therapy for preventing cardiovascular disease in post-menopausal women.
High quality evidence is found that hormone therapy in both primary and secondary prevention conferred no protective effects for all-cause mortality, cardiovascular death, non-fatal myocardial infarction, angina, or revascularisation; the findings are dominated by the three largest trials. Expand